ARGX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

ARGX ▼ -4.55% at T+5d

LONG call ✗ call lost -4.55% · α vs SPY -4.47% · entry $813.28 → $776.26

Next anchor: T+20d due yesterday

Currently $884.00 · +8.70% from $813.28 entry

Entry anchored
May 8, 03:59 PM ET
via Databento tick

T+1d

0.00%

call 0.00% · α +0.14%

$813.28

settled 4w ago

T+5d

-4.55%

call -4.55% · α -4.47%

$776.26

settled 26d ago

T+20d

—

call — · α —

—

due yesterday

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

FDA approved label expansion for VYVGART and VYVGART Hytrulo to treat all serotypes of generalized myasthenia gravis (gMG), including anti-MuSK, anti-LRP4, and triple-seronegative patients. The expansion is based on positive Phase 3 ADAPT SERON data and increases the addressable gMG patient population by approximately 20%.

Actionable Insight

This FDA label expansion significantly increases the total addressable market for VYVGART in gMG. Monitor upcoming catalysts including ADAPT OCULUS (ocular MG) and ADAPT Jr (pediatric) readouts, which could further expand the label. Watch for competitive dynamics from UCB's Rystiggo and JNJ's nipocalimab.

Key Facts

FDA approved label expansion for VYVGART and VYVGART Hytrulo to cover all gMG serotypes (anti-AChR, anti-MuSK, anti-LRP4, triple seronegative).
Approval based on Phase 3 ADAPT SERON study (n=119) showing significant improvement in MG-ADL score at week 4 (p=0.0068).
Expands addressable gMG patients by ~20% (non-AChR-Ab positive patients).
VYVGART now has the broadest MG label to date.

Financial Impact

Expands addressable market by ~20% in gMG; VYVGART's current annual revenue is ~$2B, expansion could add several hundred million in peak sales.

revenuepatient population

Risk Factors

Competition from other FcRn inhibitors (UCB, JNJ).
Potential pricing/reimbursement pressures.
Safety signals in broader real-world use.

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

92% bullish (25 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3291372

6 reports for ARGX

T+1T+5T+20T+60

67% Hit rate 2 of 3 directional calls best @ T+20▲ +6.94%Apr 30, 2026

Filters

Reports for ARGX — sortable, filterable
	Type				Now
Jun 3, 2026 6d ago	6-K BULLISH ★ 5/10	$813.14 $842.27	▲ +3.58%	▲ +3.18%	$884.00 (+8.71%)
May 8, 2026 4w ago	Press Release BULLISH ★ 7/10	$813.28 $813.28	· 0.00%	▲ +0.14%	$884.00 (+8.70%)
May 6, 2026 4w ago	6-K NEUTRAL ★ 3/10	$787.31 $787.31	· 0.00%	▼ −0.83%	$884.00 (+12.28%)
May 6, 2026 4w ago	Press Release NEUTRAL ★ 2/10	$787.31 $787.31	· 0.00%	▼ −0.83%	$884.00 (+12.28%)
Apr 30, 2026 5w ago	Press Release BULLISH ★ 8/10	$781.72 $783.50	▲ +0.23%	▲ +0.01%	$884.00 (+13.08%)
Apr 20, 2026 7w ago	6-K BULLISH ★ 8/10	$834.45 $805.38	▼ −3.48%	▼ −2.83%	$884.00 (+5.94%)

US Market Status

Market Closed — Opens Thu (10h 7m)

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access